Dietary t10,c12-CLA but not c9,t11 CLA reduces adipocyte size in the absence of changes in the adipose renin-angiotensin system in fa/fa Zucker rats.
In obesity, increased activity of the local renin-angiotensin system (RAS) and enlarged adipocytes with altered adipokine production are linked to the development of obesity-related health problems and cardiovascular disease. Mixtures of conjugated linoleic acid (CLA) isomers have been shown to reduce adipocyte size and alter the production of adipokines. The objective of this study was to investigate the effects of feeding individual CLA isomers on adipocyte size and adipokines associated with the local adipose RAS. Male fa/fa Zucker rats received either (a) control, (b) cis(c)9,trans(t)11-CLA, or (c) t10,c12-CLA diet for 8 weeks. The t10,c12-CLA isomer reduced adipocyte size and increased cell number in epididymal adipose tissue. RT-PCR and Western blot analysis revealed that neither CLA isomer altered mRNA or protein levels of angiotensinogen or AngII receptors in adipose tissue. Likewise, levels of the pro-inflammatory cytokines TNF-α and IL-6 or the anti-inflammatory cytokine IL-10 were unchanged in adipose tissue. Similarly, neither CLA isomer had any effect on phosphorylation nor DNA binding of NF-κB. Our results suggest that although the t10,c12-CLA isomer had beneficial effects on reducing adipocyte size in obese rats, this did not translate into changes in the local adipose RAS or associated adipokines.
DeClercq
Vanessa
V
Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, MB, R2H 2A6, Canada. vdeclercq@sbrc.ca
Zahradka
Peter
P
Taylor
Carla G
CG
D017667:Adipocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D054392:Adipokines / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D048429:Cell Size / Q000187:drug effects; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004435:Eating / Q000187:drug effects; D006128:Growth / Q000187:drug effects; D007536:Isomerism; D044243:Linoleic Acids, Conjugated / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D009765:Obesity / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D051381:Rats; D011924:Rats, Zucker; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D013329:Structure-Activity Relationship
D054392:Adipokines; D004042:Dietary Fats, Unsaturated; D044243:Linoleic Acids, Conjugated; D016328:NF-kappa B